ENCell
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
ENCell is a South Korean biotech company focused on cell therapy, treatments that use living cells to address disease, listed on KOSDAQ, Korea's tech and small-cap stock exchange.
Its products are intended for use in medical and clinical settings, placing it within the broader biopharmaceutical supply chain. ENCell has no subsidiaries and operates as a standalone entity.
Summary is AI-generated and may contain errors · figures from DART filings
ENCell in five facts
What does ENCell do?
ENCell is a South Korean biotech company focused on cell therapy, treatments that use living cells to address disease, listed on KOSDAQ, Korea's tech and small-cap stock exchange.
Where is ENCell listed and in which sector?
ENCell (Korean name: 이엔셀) trades under KRX code 456070 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is ENCell?
Its market capitalisation was US$41.9M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were ENCell's latest annual revenue and operating profit?
For fiscal year 2025, ENCell reported revenue of US$4M, an operating loss of US$13.5M and a net loss of US$12.2M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was down 27.1% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Supply contract signed
ENCell updated a previously disclosed supply contract, now worth US$1.27M, about 26.6% of its recent annual revenue, running through Aug 2027.
Supply contract · Jun 1 - Supply contract signed
ENCell disclosed a supply contract, worth US$408K, about 11.41% of its recent annual revenue, running through Jul 2027.
Supply contract · Apr 20